

## Mechanism of Squalene Cyclization: The Chiral Origin of the C-22 Hydrogen Atoms of Fusidic Acid

By E. CASPI\* and R. C. EBERSOLE

(The Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545)

and W. O. GODTFREDSSEN and S. VANGEDAL

(Leo Pharmaceutical Products, Ballerup, Denmark)

**Summary** The C-2 protons of mevalonic acid are incorporated with retention of configuration into C-22 of fusidic acid; this finding excludes the intermediacy of products with a  $\Delta^{20(22)}$  double bond in the formation of a  $\Delta^{17(20)}$  double bond in fusidic acid.

THE difficulty<sup>1,2</sup> of rationalizing the collapse of cation (1)<sup>3</sup> to protosterol antibiotics like fusidic acid (2a) and others<sup>4</sup> all having the *Z* geometry at  $\Delta^{17(20)}$  has been pointed out. Stabilization of (1) through direct elimination of the 17 $\beta$ -proton (route 'a') would lead according to Cornforth's hypothesis<sup>3b</sup> to the wrong geometry about the 17(20) double bond.<sup>1,2</sup> Additionally in such a process the cyclase system of *F. coccineum* would be expected to obviate the backbone rearrangement<sup>3</sup> through a kinetically controlled stabilization of (1) (route 'a'). In contrast during the enzymatic transformation of (1) into lanosterol, it has been suggested that the cyclase system exerts only a marginal influence.<sup>5</sup>

The interpretational difficulty could be alleviated were the formation of (2a) to proceed through a  $\Delta^{20(22)}$  intermediate (3a) (1; route 'b') as noted by Corey *et al.*<sup>6</sup> for the analogue (3b). Enzymatic isomerization of (3a) could afford (2a) (origin of C-22 hydrogens not assigned). Rotation around C-17(20) of (3a) would permit positioning of the side chain and the 17-hydrogen suitable for the formation of a  $\Delta^{17(20)}$  double bond in (2a).


The presence of a  $\Delta^{20(22)}$  intermediate was supported by an observation that incubation<sup>1,7</sup> of (3*RS*;2*S*)-[2-<sup>14</sup>C,2-<sup>3</sup>H]-mevalonic acid (MVA) (<sup>3</sup>H:<sup>14</sup>C ratio 5.26:1 atomic ratio 1:1) with *F. coccineum* gave *S*-fusidic acid (2a) with a <sup>3</sup>H:<sup>14</sup>C ratio of 4.65:1, corresponding to the incorporation of 5.3 atoms of tritium and 6 atoms of <sup>14</sup>C. In the case of *R*-fusidic acid (2a) biosynthesized from (3*RS*;2*R*)-[2-<sup>14</sup>C,2-<sup>3</sup>H]-MVA (<sup>3</sup>H:<sup>14</sup>C ratio 5.15:1) the <sup>3</sup>H:<sup>14</sup>C ratio of 5.04:1 corresponded to an atomic ratio of 6:6. The results with (2*S*)-[2-<sup>14</sup>C,2-<sup>3</sup>H]-MVA could be interpreted as arising from the

TABLE


Experiment with:			I; (2 <i>R</i> )-[2- <sup>3</sup> H,2- <sup>14</sup> C]MVA <sup>3</sup> H: <sup>14</sup> C ratio			II; (2 <i>S</i> )-[2- <sup>3</sup> H,2- <sup>14</sup> C]MVA <sup>3</sup> H: <sup>14</sup> C ratio		
No.	Product	Derivative counted	<sup>14</sup> C-Spec. act. <sup>a</sup>	Isotopic	Atomic	<sup>14</sup> C-Spec. act. <sup>a</sup>	Isotopic	Atomic
1.	Mevalonic acid .. .. .	<i>N</i> -Diphenylmethylamide	8.79	5.15	1.02:1	4.75	5.26	1.13:1
2.	Methyl fusidate .. .. .	(2 <i>b</i> )	86.7	5.04	6.00:6	82.4	4.65	6.00:6
3.	Methyl dihydrofusidate .. .. .	(2 <i>c</i> )	85.6	5.05	6.00:6	82.5	4.62	5.96:6
4.	6-Methylheptane-1,2-diol .. .. .	(4 <i>b</i> )	30.2	4.92	1.95:2	29.0	4.58	1.97:2
5.	5-Methylhexan-1-al .. .. .	(4 <i>d</i> )	30.4	5.04	2.00:2	29.0	4.66	2.00:2
6.	4-Methylpentan-1-ol .. .. .	(5 <i>c</i> )	2.7	5.02	1.99:2	4.0	4.60	1.98:2
7.	4-Methylpentan-1-al .. .. .	(6 <i>b</i> )	1.5	3.02	1.20:2	4.9	4.54	1.95:2
8.	Methyl 4-methylpentanoate .. .. .	(6 <i>d</i> )	—	—	—	—	2.38	1.02:2

<sup>a</sup> D.p.m. per mmol × 10<sup>4</sup>; entries 1, 6 and 7 were counted at higher dilutions.


loss of a 22-*pro-S* hydrogen *via* pathway [*b'* shown in (1)] in the biosynthesis of (2*a*). The specimens of *R* and *S*-fusidic acid were thus degraded as shown in the Scheme and the chirality and <sup>3</sup>H content at C-22 determined.



- (1)  
 ⊗ — prosthetic group or(+)charge  
 ● — C-2 carbon of MVA  
 H<sub>R</sub> and H<sub>S</sub> — protons from the 2-*pro-R* and 2-*pro-S* of MVA  
 ⊕ — protons from 4-*pro-R* of MVA.




- (2)  
 a ; R = H  
 b ; R = Me  
 c ; R = Me ; no Δ<sup>24</sup>




- (3)  
 a ; X = Me  
 b ; X = H


oxidation of the alcohol (5*b*) to aldehyde (6*a*) proceeded without loss of tritium. Hence if (5*b*) had a tritium atom at C-1 the alcohol must have the 1*S* configuration. Consequently the diene<sup>1,12</sup> (7) (from *S*-fusidic acid) was oxidized<sup>13</sup> to (6*c*) which was purified as the methyl ester (6*d*) by g.l.c. The <sup>3</sup>H:<sup>14</sup>C ratio of (6*d*) indicates that of the two <sup>3</sup>H atoms present in (5*b*) only one was retained. Therefore




- (4)  
 a ; R<sup>1</sup> = CH<sub>2</sub>OH ; R<sup>2</sup> = OH  
 b ; R<sup>1</sup> = CH<sub>2</sub>O-CO-NHPH ; R<sup>2</sup> = O-CO-NHPH  
 c ; R<sup>1</sup> = H ; R<sup>2</sup> = O  
 d ; R<sup>1</sup> = H ; R<sup>2</sup> = dimedone derivative




- (5)  
 a ; R = OCHO  
 b ; R = H  
 c ; R = OC-NHPH



- (6)  
 a ; R<sup>1</sup> = H ; R<sup>2</sup> = O  
 b ; R<sup>1</sup> = H ; R<sup>2</sup> = dimedone derivative  
 c ; R<sup>1</sup> = OH ; R<sup>2</sup> = O  
 d ; R<sup>1</sup> = OMe ; R<sup>2</sup> = O



(7)



SCHEME

a ; i H<sub>2</sub>; <sup>9</sup> ii CH<sub>2</sub>N<sub>2</sub>. b ; i O<sub>3</sub>; ii LiAlH<sub>4</sub>. c ; H<sub>5</sub>IO<sub>8</sub>. d ; i CF<sub>3</sub>-COOH;<sup>10b</sup> ii LiAlH<sub>4</sub>; iii prep. g.l.c. e ; NAD<sup>+</sup>-Yeast alcohol dehydrogenase (YADH). f ; i LiCl-HCO-NMe<sub>2</sub>; <sup>12</sup> ii CH<sub>2</sub>N<sub>2</sub>. g ; i RuO<sub>4</sub>; <sup>13</sup> ii CH<sub>2</sub>N<sub>2</sub>; iii prep. g.l.c.

The products† obtained from *R*-fusidic (Table; Experiment I; entries 2—6) exhibited <sup>3</sup>H:<sup>14</sup>C ratios which corresponded to the predicted<sup>1,8</sup> atomic ratios. One atom of tritium‡ was lost on the NAD<sup>+</sup>-YADH oxidation of (5*b*) to (6*a*) (Experiment I; entries 6, 7), thus establishing the 1*R* configuration of the alcohol.<sup>11</sup>

The products from the *S*-fusidic acid had constant <sup>3</sup>H:<sup>14</sup>C ratios (Experiment II; entries 2—7). Clearly NAD<sup>+</sup>-YADH

† All the compounds were homogenous by g.l.c. or t.l.c. Derivatives were identified by n.m.r., mass, and i.r. spectroscopy, *etc.*, and by comparison with authentic samples.

‡ The removal of only 0.8 atom of tritium may have been caused by partial air oxidation of the alcohol (see ref. 11).

one atom of tritium must be present at C-1 of (5*b*) and (6*a*). It follows that a tritium atom originating from (2*S*)-[2-<sup>14</sup>C,-2-<sup>3</sup>H]-MVA is present at the 22-*pro-S* position of the derived *S*-fusidic acid.

The results demonstrate that the C-2 protons of MVA are incorporated into C-22 of fusidic acid with retention of their stereochemical integrity. The intermediacy of a Δ<sup>20(22)</sup>

precursor is thus excluded. Because the C-13 hydrogen of fusidic acid is derived from the 4-*pro R* proton of MVA,<sup>1</sup>  $\Delta^{12}$  or  $\Delta^{13(17)}$  intermediates also cannot be involved in the biosynthesis. Hence it seems that the stabilization of (1) in the formation of (2a) cannot be rationalized solely on an organic chemical basis<sup>5</sup> without some enzyme participation.<sup>1</sup>

This work was supported by Grants from the National Institutes of Health. The authors thank Dr. L. J. Mulheirn for preliminary experiments.

(Received, 7th August 1972; Com. 1382.)

<sup>1</sup> L. J. Mulheirn and E. Caspi, *J. Biol. Chem.*, 1971, **246**, 2494; E. Caspi and L. J. Mulheirn, *J. Amer. Chem. Soc.*, 1970, **92**, 404.

<sup>2</sup> L. J. Mulheirn and P. J. Ramm, *Chem. Soc. Rev.*, 1972, **1**, 259.

<sup>3</sup> (a) A. Eschenmoser, L. Ruzicka, O. Jeger, and D. Arigoni, *Helv. Chim. Acta*, 1955, **38**, 1890; (b) J. W. Cornforth, *Angew. Chem. Internat. Edn.* 1968, **7**, 903.

<sup>4</sup> (a) T. G. Halsall, E. R. H. Jones, G. Lowe, and C. E. Newall, *Chem. Comm.*, 1966, 685; P. Oxley, *ibid.*, p. 729; (b) S. Okuda, S. Iwasaki, M. I. Sair, Y. Machida, A. Inoue, K. Tsuda, and Y. Nakayama, *Tetrahedron Letters*, 1967, 2295; W. von Daehne, H. Lorch, and W. O. Godtfredsen, *ibid.*, 1968, 4843.

<sup>5</sup> E. E. van Tamelen and J. H. Freed, *J. Amer. Chem. Soc.*, 1970, **92**, 7206; E. E. van Tamelen, R. P. Hanzlik, R. B. Clayton, and A. L. Burlingame, *ibid.*, p. 2137.

<sup>6</sup> E. J. Corey, P. R. O. de Montellano, and H. Yamamoto, *J. Amer. Chem. Soc.*, 1968, **90**, 6255; E. J. Corey, K. Lin, and H. Yamamoto, *ibid.*, 1969, **91**, 2132.

<sup>7</sup> W. O. Godtfredsen, W. von Daehne, S. Vangedal, A. Marquet, D. Arigoni, and A. Melera, *Tetrahedron*, 1965, **21**, 3505.

<sup>8</sup> G. Popjak and J. W. Cornforth, *Biochem. J.*, 1966, **101**, 553.

<sup>9</sup> W. O. Godtfredsen and S. Vangedal, *Tetrahedron*, 1962, **18**, 1029.

<sup>10</sup> (a) J. B. Greig, K. R. Varma, and E. Caspi, *J. Amer. Chem. Soc.*, 1971, **93**, 760; (b) M. F. Hawthorne, W. D. Emmons, and K. S. McCallum, *ibid.*, 1958, **80**, 6393.

<sup>11</sup> J. B. Greig, K. R. Varma, and E. Caspi, *J. Amer. Chem. Soc.*, 1971, **93**, 760; E. Caspi, K. R. Varma, and J. B. Greig, *Chem. Comm.*, 1969, 45; K. R. Varma and E. Caspi, *J. Org. Chem.*, 1969, **34**, 2489.

<sup>12</sup> W. O. Godtfredsen, W. von Daehne, and S. Vangedal, *Chem. Comm.*, 1966, 638.

<sup>13</sup> D. M. Piatak, H. B. Bhat, and E. Caspi, *J. Org. Chem.*, 1969, **34**, 112; D. M. Piatak, G. Herbst, J. Wicha, and E. Caspi, *ibid.*, p. 116.